Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Pavel Nemec

Showing results (21-30 of 27) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 27 results.
International Journal of Molecular Sciences|April 13, 2024
Disease-Causing <i>TIMP3</i> Variants and Deep Phenotyping of Two Czech Families with Sorsby Fundus Dystrophy Associated with Novel p.(Tyr152Cys) MutationAndrea Vergaro, Monika Pankievic, Jana Jedlickova, et al.
Genomics|July 9, 2013
Cell cycle genes co-expression in multiple myeloma and plasma cell leukemiaFedor Kryukov, Elena Dementyeva, Lenka Kubiczkova, et al.
Bone|August 23, 2017
ARQ 087 inhibits FGFR signaling and rescues aberrant cell proliferation and differentiation in experimental models of craniosynostoses and chondrodysplasias caused by activating mutations in FGFR1, FGFR2 and FGFR3Lukas Balek, Iva Gudernova, Iva Vesela, et al.
Biomed Research International|July 3, 2014
Genome-wide screening of cytogenetic abnormalities in multiple myeloma patients using array-CGH technique: a Czech multicenter experienceJan Smetana, Jan Frohlich, Romana Zaoralova, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|December 17, 2009
Gain of 1q21 is an unfavorable genetic prognostic factor for multiple myeloma patients treated with high-dose chemotherapyPavel Nemec, Zuzana Zemanova, Henrieta Greslikova, et al.
Leukemia & Lymphoma|October 26, 2011
Complex karyotype and translocation t(4;14) define patients with high-risk newly diagnosed multiple myeloma: results of CMG2002 trialPavel Nemec, Zuzana Zemanova, Petr Kuglik, et al.
Clinical Lymphoma, Myeloma & Leukemia|January 8, 2013
Gain(1)(q21) is an unfavorable genetic prognostic factor for patients with relapsed multiple myeloma treated with thalidomide but not for those treated with bortezomibJan Smetana, Kristina Berankova, Romana Zaoralova, et al.
Pageof 3

Showing results (21-30 of 27) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 27 results.
International Journal of Molecular Sciences|April 13, 2024
Disease-Causing <i>TIMP3</i> Variants and Deep Phenotyping of Two Czech Families with Sorsby Fundus Dystrophy Associated with Novel p.(Tyr152Cys) MutationAndrea Vergaro, Monika Pankievic, Jana Jedlickova, et al.
Genomics|July 9, 2013
Cell cycle genes co-expression in multiple myeloma and plasma cell leukemiaFedor Kryukov, Elena Dementyeva, Lenka Kubiczkova, et al.
Bone|August 23, 2017
ARQ 087 inhibits FGFR signaling and rescues aberrant cell proliferation and differentiation in experimental models of craniosynostoses and chondrodysplasias caused by activating mutations in FGFR1, FGFR2 and FGFR3Lukas Balek, Iva Gudernova, Iva Vesela, et al.
Biomed Research International|July 3, 2014
Genome-wide screening of cytogenetic abnormalities in multiple myeloma patients using array-CGH technique: a Czech multicenter experienceJan Smetana, Jan Frohlich, Romana Zaoralova, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|December 17, 2009
Gain of 1q21 is an unfavorable genetic prognostic factor for multiple myeloma patients treated with high-dose chemotherapyPavel Nemec, Zuzana Zemanova, Henrieta Greslikova, et al.
Leukemia & Lymphoma|October 26, 2011
Complex karyotype and translocation t(4;14) define patients with high-risk newly diagnosed multiple myeloma: results of CMG2002 trialPavel Nemec, Zuzana Zemanova, Petr Kuglik, et al.
Clinical Lymphoma, Myeloma & Leukemia|January 8, 2013
Gain(1)(q21) is an unfavorable genetic prognostic factor for patients with relapsed multiple myeloma treated with thalidomide but not for those treated with bortezomibJan Smetana, Kristina Berankova, Romana Zaoralova, et al.
Pageof 3